



PRESS RELEASE

FOR IMMEDIATE RELEASE

NORDIC LIFE SCIENCE PIPELINE LAUNCHES A PIVOTAL CLINICAL STUDY FOR SQIN™, AN ULTRA-MOISTURIZER AGAINST XEROSIS (DRY SKIN) FOR PEOPLE WITH MOBILITY IMPAIRMENT.

QUEBEC CITY, CANADA, April 8, 2015 – Today, NORDIC LIFE SCIENCE PIPELINE is proud to launch the recruitment and testing of volunteers for the double-blind, randomized clinical study (phase II) of SQIN™, the first dermatologic product of its new biocosmeceutical division called NORBIODERM. *Nordic* is in the footsteps of Sanofi, GSK, and Valeant, world leading pharmaceutical companies developing and commercializing both pharmaceutical products and over-the-counter (OTC) skin care products. In contrast, NORDIC intends to be first in specializing on dermatological products for chronic dry skin conditions (xerosis) typically experienced by individuals with paralysis and/or mobility impairment. Pending upon these results, commercialization of SQIN™ may be announced as early as Q3-2015.

About cosmeceutics

Cosmeceutics is a new science focusing on identification of active ingredients for cosmeceutical and dermatological products. Specifically, it attempts to apply approaches and know-how from the pharmaceutical industry into the cosmeceutic field in order to propose innovative products that can truly improve specific skin problems. Laval University is a pioneer with the first program (B.Sc.) ever in Canada in Cosmeceutical Chemistry.

About skin problems associated with reduced mobility and paralysis

In North America, 1 out of 50 people suffer of mobility impairment due to paralysis. This is more than 6 million Americans currently living with traumatic spinal cord injury, multiple sclerosis, Parkinson's disease, stroke, Lou Gehrig's disease, muscular dystrophy or amputation. Including mobility problems also found in elderly, mobility impairment and related-skin problems affects more than 1 billion people worldwide. Overall, mobility problems are associated with comparable secondary health concerns including chronic dry skin that poorly responds to standard moisturizing creams. Compelling scientific evidence suggests that this may be attributed to the multifactorial character of what leads to such chronic dry skin – e.g., impaired circulatory system (poor circulation, anemia), immune problems, and mechanical factors (specific skin areas exposed, rubbed or compressed) leading to sensitive, very dry, irritated, degraded and infected skin.

About Nordic Life Science Pipeline Inc.

Originally a spinoff of Laval University, this biopharmaceutical Quebec City-based company is specialized since 2009 in first-in-class branded neurological products aimed at restoring vital functions (locomotion, micturition, defecation, reproductive functions) in people suffering of spinal cord injury, multiple sclerosis, Parkinson's disease or diabetic neuropathy. NORDIC is currently assessing also in a clinical Phase IIa trial the safety and efficacy in paralytics of a tri-therapy called Spinalon™ that has been shown to potently trigger in paraplegic animals 'on-demand' episodes of basic walking on a treadmill within only 15 minutes post-administration.